{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T09:51:26Z","timestamp":1781949086869,"version":"3.54.5"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012330","name":"Okayama University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012330","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12282-026-01846-3","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T10:39:05Z","timestamp":1776335945000},"page":"829-838","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6812-6150","authenticated-orcid":false,"given":"Kiyo","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ishitobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Tsukioki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroji","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumikata","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Sadachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riku","family":"Kajikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Sagara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Shigematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Nozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Terata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Ishiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadahiko","family":"Shien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"issue":"1","key":"1846_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/annonc\/mds248","volume":"24","author":"MV Dieci","year":"2013","unstructured":"Dieci MV, Barbieri E, Piacentini F, Gamucci T, Crivellari D, Guarneri V, et al. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis. Ann Oncol. 2013;24(1):101\u20138. https:\/\/doi.org\/10.1093\/annonc\/mds248.","journal-title":"Ann Oncol"},{"issue":"5","key":"1846_CR2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1200\/JCO.2011.36.5083","volume":"30","author":"N Niikura","year":"2012","unstructured":"Niikura N, Liu J, Hayashi N, Kogawa T, Saji S, Iwata H, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol. 2012;30(5):593\u20139. https:\/\/doi.org\/10.1200\/JCO.2011.36.5083.","journal-title":"J Clin Oncol"},{"issue":"21","key":"1846_CR3","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1200\/JCO.2011.37.2482","volume":"30","author":"LS Lindstr\u00f6m","year":"2012","unstructured":"Lindstr\u00f6m LS, Karlsson E, Wilking UM, Blomqvist C, Ryd\u00e9n L, Fern\u00f6 M, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and HER2 are unstable throughout tumor progression. J Clin Oncol. 2012;30(21):2601\u20138. https:\/\/doi.org\/10.1200\/JCO.2011.37.2482.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1846_CR4","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/jjco\/hys115","volume":"42","author":"T Shien","year":"2012","unstructured":"Shien T, Nakamura K, Shibata T, Kinoshita T, Aogi K, Fujisawa T, et al. A randomized controlled trial comparing primary tumor resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group study JCOG1017. Jpn J Clin Oncol. 2012;42(10):970\u20133. https:\/\/doi.org\/10.1093\/jjco\/hys115.","journal-title":"Jpn J Clin Oncol"},{"key":"1846_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03097-z","author":"T Shien","year":"2025","unstructured":"Shien T, Hara F, Aogi K, Yanagida Y, Tsuneizumi M, Yamamoto N. Primary tumor resection plus systemic therapy versus systemic therapy alone in metastatic breast cancer (JCOG1017, PRIM-BC): a randomized clinical trial. Br J Cancer. 2025. https:\/\/doi.org\/10.1038\/s41416-025-03097-z.","journal-title":"Br J Cancer"},{"issue":"2","key":"1846_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"1846_CR7","volume-title":"Breast Cancer Clinical Practice Guidelines 2022 Edition","author":"The Japanese Breast Cancer Society","year":"2022","unstructured":"The Japanese Breast Cancer Society. Breast Cancer Clinical Practice Guidelines 2022 Edition. Kanehara & Co., Ltd; 2022."},{"issue":"9","key":"1846_CR8","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1200\/JCO.21.02006","volume":"40","author":"SA Khan","year":"2022","unstructured":"Khan SA, Zhao F, Goldstein LJ, Hurria A, Albain KS, Rugo HS, et al. Early local therapy for the primary site in de novo stage IV breast cancer: results of a randomized clinical trial (EA2108). J Clin Oncol. 2022;40(9):978\u201387. https:\/\/doi.org\/10.1200\/JCO.21.02006.","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1007\/s12282-026-01874-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000}}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01846-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01846-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01846-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T09:22:14Z","timestamp":1781947334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-026-01846-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1846"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01846-3","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12282-026-01874-z","URL":"https:\/\/doi.org\/10.1007\/s12282-026-01874-z","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Shien reported grants from the Ministry of Health, Labour and Welfare of Japan and from the Japan Agency for Medical Research and Development (AMED) during the conduct of the study, as well as personal fees from Pfizer, Chugai, Lilly, Daiichi Sankyo, MSD, Eizai, AstraZeneca, Taiho, Nihonkayaku, Gilead. Dr. Hara reported the personal fees from Pfizer, Ili Lilly, Daiichi Sankyo, Kyowa Kirin, Chugai, MSD. Dr. Ogawa reported the grants from Japan Agency for Medical Research and Development and Ministry of Health, Labour and Welfare, Japan. Dr. Fukuda reported the grants from National Cancer Center and AstraZeneca, Ono Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co., Ltd, Takeda Pharmaceutical Company Limited and the personal fees from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., CMIC Co., Ltd. Dr. Iwata reported the grants from Pfizer and Chugai, Daiichi Sankyo, AstraZeneca and personal fees from Daiichi Sankyo, Chugai, AstraZeneca, Lilly, MSD, Pfizer, Taiho, Kyowa Kirin. No other disclosures were reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent including the secondary use of data was obtained from all individual participants enrolled in JCOG1017.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}